كندا - الفرنسية - Health Canada

pfizer consumer healthcare a division of pfizer canada ulc - ibuprofène (ibuprofène sodique dihydraté) - comprimé - 200mg - ibuprofène (ibuprofène sodique dihydraté) 200mg - other nonsteroidal antiimflammatory agents

كندا - الفرنسية - Health Canada

pfizer consumer healthcare a division of pfizer canada ulc - ibuprofène (ibuprofène sodique dihydraté) - comprimé - 400mg - ibuprofène (ibuprofène sodique dihydraté) 400mg - other nonsteroidal antiimflammatory agents

كندا - الفرنسية - Health Canada

pfizer consumer healthcare a division of pfizer canada ulc - ibuprofène (ibuprofène sodique dihydraté) - comprimé - 200mg - ibuprofène (ibuprofène sodique dihydraté) 200mg - other nonsteroidal antiimflammatory agents

كندا - الفرنسية - Health Canada

pfizer consumer healthcare a division of pfizer canada ulc - ibuprofène (ibuprofène sodique dihydraté) - comprimé - 200mg - ibuprofène (ibuprofène sodique dihydraté) 200mg - other nonsteroidal antiimflammatory agents

كندا - الفرنسية - Health Canada

pfizer consumer healthcare a division of pfizer canada ulc - ibuprofène (ibuprofène sodique dihydraté) - comprimé - 400mg - ibuprofène (ibuprofène sodique dihydraté) 400mg - other nonsteroidal antiimflammatory agents

كندا - الفرنسية - Health Canada

pendopharm division of pharmascience inc - ibuprofène - comprimé - 200mg - ibuprofène 200mg - other nonsteroidal antiimflammatory agents

كندا - الفرنسية - Health Canada

pendopharm division of pharmascience inc - fluconazole - capsule - 150mg - fluconazole 150mg - azoles

الاتحاد الأوروبي - الفرنسية - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - fièvre hémorragique À virus ebola - vaccins - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

الاتحاد الأوروبي - الفرنسية - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - poulet - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

الاتحاد الأوروبي - الفرنسية - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.